Ivan Foeldvari
Ivan Foeldvari is an expert in Rheumatology at Schön Klinik Hamburg Eilbek (Germany). As of June 2026, ScienceLeadR ranks Ivan Foeldvari in the top 1% of experts worldwide for Arthritis and Autoimmune Diseases. Ivan Foeldvari has authored 392 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 1 of them ongoing. SLR score: 1,224 (community average: 125). How the SLR is computed.
LeadR Profile
Rheumatology
Subspecialties: Immunology - Dermatology - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
I have a lifetime interest in pediatric rheumatology. I begin to be interested in juvenile sclerosis during my fellowship in Vancouver. I had one of my first ACR Congress Posters with Prof Tom Lehman from Cornell University in New York USA. I conducted a cross sectional multinational survey of clinical features, which was published 2000, containing the largest number of patients ever surveyed. I am founding member of the juvenile scleroderma working group of the Pediatric Rheumatology European Society and was leader for several years I am lead of the clinical affairs of the juvenile scleroderma working group of the Pediatric Rheumatology European Society since 2023. I am member of EUSTAR and leading the pediatric working group of the Scleroderma Clinical Trial Consortium. I am the PI and founder of the Juvenile Scleroderma Inception Cohort, which is currently the largest cohort of juvenile Systemic Scleroderma in the world.
I am organizing the annual Hamburg meeting regarding juvenile Scleroderma for the last 18 years.Based on these meetings we published guidance for juvenile localized scleroderma, Raynaud’s in children and juvenile systemic scleroderma assessment and treatment. I was part of the SHARE initiative for juvenile systemic scleroderma and I am the first author of the guidance publication for “best treatment” and for stemm cell therapy.
Our center is one of the leading centers in Europe for Phase II, III and IV studies regarding upcoming new medications for juvenile systemic sclerosis, juvenile idiopathic arthritis and JIA associated uveitis.
Organizations
Career arc: 1995 - 2026
Number : 392
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 10
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis NCT04527380 — arthritis, psoriatic, safety, spondylitis, ankylosing, arthritis, spondylitis, adalimumab, arthritis, juvenile, child | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map